Results 21 to 30 of about 1,481 (212)
Antithrombin deficiency in pregnancy [PDF]
We present a case of a 39-year-old, gravida 3 para 2, Chinese female with a history of inherited type 1 Antithrombin deficiency and multiple prior episodes of venous thromboembolism. She presented at 29+4 weeks' gestation with severe pre-eclampsia complicated by haemolysis, elevated liver enzymes and low platelet (HELLP) syndrome.
Shivani, Durai +2 more
openaire +2 more sources
An artificial bifunctional N‐deacetylase/N‐sulfotransferase was engineered in Escherichia coli by combining screened N‐deacetylases with an NST domain. The integrated engineering strategy improved enzyme performance. The optimized enzyme efficiently converted heparosan into N‐sulfated heparosan, addressing a key bottleneck in microbial heparin ...
Xintong Xi +8 more
wiley +1 more source
Safety and Feasibility of Magnetic Separation‐Based Blood Purification
We present the preclinical biological safety and translational feasibility of a magnetic nanoparticle‐based extracorporeal blood purification platform for removal of disease‐causing blood factors. ISO 10993‐compliant studies and exaggerated worst‐case exposure models demonstrate efficient nanoparticle extraction (≥99.9%), favorable biocompatibility ...
Carlos A. Mora +11 more
wiley +1 more source
Engineering Biology Beyond Single Genes: Advances and Challenges in Multiplex Genome Editing
Multiplex genome editing is transforming genome engineering from single‐gene perturbation to network‐level control, yet its broader application remains limited by challenges in gRNA array engineering, delivery technologies, and safety management. Emerging AI‐driven approaches are accelerating guide RNA design and CRISPR effector optimization for ...
Linli Wang, Yongbin Liu, Hongbing Han
wiley +1 more source
Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration
The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang +13 more
wiley +1 more source
Thrombin-Fibrin(ogen) Interactions, Host Defense and Risk of Thrombosis
Fibrinogen is a well-known risk factor for arterial and venous thrombosis. Its function is not restricted to clot formation, however, as it partakes in a complex interplay between thrombin, soluble plasma fibrinogen, and deposited fibrin matrices ...
Hemker, H Coenraad +9 more
core +1 more source
Pectin, a versatile natural polymer, is extracted through conventional and emerging green extraction methods, offering multifunctional bioactive properties useful in food, pharmaceutical, and environmental applications. ABSTRACT Pectin, a molecular tapestry woven from diverse polysaccharides, holds a pivotal role across food, pharmaceutical, and ...
Afra Anika Rafique +3 more
wiley +1 more source
This study established and validated comprehensive RIs for four key thrombus biomarkers (TAT, PIC, TM, and t‐PAIC) in a Chinese population using the Hoffmann and Bhattacharya indirect methods on a large clinical dataset. The tailored RIs offer a practical tool for early detection and risk assessment of thrombotic diseases, supporting more precise and ...
Lei Zhang +3 more
wiley +1 more source
This propensity score‐matched study compared unfractionated heparin (UFH) and low‐molecular‐weight heparin (LMWH) in 1362 sepsis patients, finding that both significantly improved survival without increasing 90‐day bleeding risk. However, their therapeutic mechanisms differed: UFH demonstrated broader anti‐inflammatory effects by reducing IL‐6, IL‐8 ...
Peili Chen +7 more
wiley +1 more source
Hemophilia A: An Ideal Disease for Prenatal Therapy
ABSTRACT Hemophilia A (HA) is the most common inherited coagulation defect. Current state‐of‐the‐art treatment consists of frequent administration of prophylactic infusions of coagulation factor VIII (FVIII) protein or bispecific antibodies that replace the cofactor function of FVIIIa to maintain hemostasis. However, these treatments are far from ideal,
Christopher D. Porada +2 more
wiley +1 more source

